Victory Capital Management Inc. Acquires 25,980 Shares of CELYAD SA/ADR (CYAD)
Victory Capital Management Inc. increased its holdings in shares of CELYAD SA/ADR (NASDAQ:CYAD) by 4.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 672,331 shares of the company’s stock after purchasing an additional 25,980 shares during the period. Victory Capital Management Inc. owned 0.07% of CELYAD SA/ADR worth $13,716,000 as of its most recent SEC filing.
Separately, Wells Fargo & Company MN boosted its position in shares of CELYAD SA/ADR by 1,109.0% in the third quarter. Wells Fargo & Company MN now owns 6,045 shares of the company’s stock worth $160,000 after acquiring an additional 5,545 shares during the last quarter. 7.89% of the stock is currently owned by hedge funds and other institutional investors.
Several equities research analysts recently issued reports on CYAD shares. William Blair reissued a “buy” rating on shares of CELYAD SA/ADR in a research report on Monday, May 13th. HC Wainwright lifted their price target on shares of CELYAD SA/ADR from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, March 19th. Zacks Investment Research cut shares of CELYAD SA/ADR from a “buy” rating to a “hold” rating in a research report on Tuesday, January 29th. Finally, Piper Jaffray Companies dropped their price objective on shares of CELYAD SA/ADR from $51.00 to $41.00 and set an “overweight” rating on the stock in a research note on Monday, April 1st. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $43.40.
ILLEGAL ACTIVITY NOTICE: “Victory Capital Management Inc. Acquires 25,980 Shares of CELYAD SA/ADR (CYAD)” was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2019/05/21/victory-capital-management-inc-acquires-25980-shares-of-celyad-sa-adr-cyad.html.
CELYAD SA/ADR Profile
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Further Reading: What Does a Sell-Side Analyst Rating Mean?
Want to see what other hedge funds are holding CYAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CELYAD SA/ADR (NASDAQ:CYAD).
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.